Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 10/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 10/20 | 0.46 |
| ▸ | ITGAL | P20701 | 10/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7141580 | 0.86 | ITGAL (0.67) | ITGB2ICAM1ITGALFFAR1 | |
| SCHEMBL7150944 | 0.86 | ITGB2 (0.52) | ITGB2ICAM1ITGAL | |
| SCHEMBL7145900 | 0.86 | ITGB2 (0.52) | ITGB2ICAM1ITGAL | |
| SCHEMBL7146694 | 0.84 | ITGB2 (0.66) | ITGB2ICAM1ITGALFFAR1 | |
| SCHEMBL7146813 | 0.84 | ITGB2 (0.51) | ITGB2ICAM1ITGALFFAR1CYP2C8 | |
| SCHEMBL7144872 | 0.84 | ITGB2 (0.44) | ITGB2ICAM1ITGALFFAR1CYP2C8 | |
| SCHEMBL7144904 | 0.84 | ITGB2 (0.51) | ITGB2ICAM1ITGAL | |
| SCHEMBL7141565 | 0.83 | ITGB2 (0.68) | ITGB2ICAM1ITGALFFAR1FFAR2 | |
| SCHEMBL7143425 | 0.75 | ITGAL (0.74) | ITGB2ICAM1ITGAL | |
| SCHEMBL7165511 | 0.67 | ITGB2 (0.50) | ITGB2ICAM1ITGALFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6521619-B2 | Bind to the interaction-domain of integrin lfa-1 interrupting enothelial cell-leukocyte adhesion | ICOS CORPORATION | 2003-02-18 | — | — | US | disclosed |
| US-20020156314-A1 | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents | ICOS CORPORATION | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156314-A1 | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents | ICAM1, VCAM1, CD47 | ITGB2 120/4885ICAM1 1/4885ITGAL 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.